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SOUHRN 
Úvod.  Aloplastické kostní štěpy se široce užívají v současnosti v kombinaci s membránami, což 
zajišťuje  realizaci řízené tkáňové regenerace  při léčbě nitrokostních parodontálních chobotů. 
Tato studie byla určena k hodnocení klinických výsledků kompozitního materiálu beta trikalcium 
fosfátu v kombinaci s kalcium sulfátem při léčení kostních parodontálních chobotů. Kombinace 
uvedených matriálů umožňuje realizaci řízené tkáňové regenerace.   
Metoda.  Celkem 47 kostních defektů u 26 pacientů bylo léčeno preparátem Fortoss® Vital 
(Biocomposites, Staffordshire, UK). Pacienti byli sledováni po 2 roky. Klinické parametry 
hodnocení zahrnovaly změny hloubky parodontálních chobotů, úroveň gingivodentálního 
spojení, gingivální recesy,přítomnost či absenci dentálního plaku, BOP na začátku (před operací) 
a za 2 roky po operaci. 
Výsledky. Po chirurgickém ošetření se zmenšila hloubka parodontálních chobotů, zvýšila se 
úroveň gingivodentálního spojení. Redukce hloubky  parodontálních chobotů poklesla po 1 a 2 
letech od operace o 1,97 ± 1.15 mm (p < 0,0001) a 2,07 ± 1,14mm (p < 0,0001 ), úroveň 
gingivodentálního spojení stoupla o  1,68 ± 1.12 mm (p < 0,0001) a 1,93 ± 1,36mm (p < 0,0001), 
gingivální recesy se zvětšily o 0,30 ± 0.71 mm (p = 0,009) a 0,14 ± 0,73mm (p = 0,571).  
Procento plošek s plakem a s pozitivním BOP se redukovalo významně za 2 roky po operaci ve 
srovnáním s vyšetřením před operací. 
Závěr. Léčba parodontálních kostních chobotů kombinací beta-trikalcium fosfátu a kalcium 
sulfátu vede k signifikantnímu zlepšení kostních parodontálních chobotů po dvou letech od 
operačním zákroku.  Pro přesnější dokumentaci efektu tohoto způsobu léčby je potřeba ještě 
dlouhodobější sledování a rozšíření počtu sledovaných defektů. 
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SUMMARY 
Background Alloplastic bone graft materials are widely been used these days in combination 
with barrier membranes to achieve guided tissue regeneration in the treatment of periodontal 
intrabony defects. This study was designed evaluate the clinical outcome of a composite 
material, beta tricalcium phosphate in combination with calcium sulphate, in the treatment of 
periodontal intra-bony defects. The combination of these materials is believed to aid in guided 
tissue regeneration owing to their properties. 
Methods Forty seven intrabony defects in 26 periodontitis patients were treated with Fortoss® 
Vital (Biocomposites, Staffordshire, UK). The patients were followed-up for 2 years. Clinical 
parameters were evaluated which included changes in probing depth (PD), clinical attachment 
level/loss (CAL) and gingival recession (GR), presence/absence of plaque and bleeding on 
probing (BOP) at baseline and at one and two years postoperatively.  
Results A decrease in probing depths (PD) was noticed in 24 patients out of the total 26 at one 
year postoperatively. At two years postoperatively, a decrease in PD was found in all patients but 
one. The number of BOP positive sites in relation to the involved teeth was reduced from 67 
(35.64 %) at baseline to 26 (13.83 %) at 1 year and 28 (14.89 %) at 2 years postoperatively. The 
number of sites with presence of plaque got decreased from 25 (26.60 %) to 15 (15.96 %) and 
then increased slightly to 18 (19.15 %) during the same interval. The mean differences in 
measurements between the baseline and one year postoperatively are a reduction of 1.97 ± 1.15 
mm (P= 0.0001) in case of PD, a gain of 1.68 ± 1.12 mm (P = 0.0001) in CAL and an increase of 
0.30 ± 0.71 mm (P = 0.009) in GR. The mean differences in measurements between the baseline 
and two years postoperatively are a reduction of 2.07 ± 1.14 mm (P = 0.0001) in case of PD, a 
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gain of 1.93 ± 1.36 mm (P = 0.0001) in CAL and an increase of 0.14 ± 0.73 mm (P = 0.571) in 
GR 
Conclusions The treatment with a combination of beta tricalcium phosphate and calcium 
sulphate led to a significantly favourable clinical improvement in periodontal intrabony defects 
two years after the surgery. A longer-term evaluation and further studies are necessary to 
completely ascertain the effectiveness of this material, and a larger sample size is needed. 
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LIST OF ABBREVIATIONS 
BMP Bone morphogenic protein 
BOP Bleeding on probing 
CAL Clinical attachment level or loss 
CPITN Community periodontal index of treatment needs 
DFBDA Demineralised freeze-dried bone allograft 
DNA Deoxyribonucleic acid 
EMD Enamel matrix derivative 
FDBA Freeze-dried bone allograft 
Fig. Figure 
GBR Guided bone regeneration 
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HIV Human immunodeficiency virus 
IGF Insulin-like growth factor 
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1 INTRODUCTION 
Dental plaque-induced periodontal diseases can be divided broadly into gingivitis and 
periodontitis based on the presence or absence of attachment loss. Gingivitis is presence of 
gingival inflammation without loss of connective tissue attachment. Periodontitis is the presence 
of gingival inflammation along with a loss of connective tissue attachment. In other words, 
periodontitis is the inflammation of periodontium characterized by apical migration of the 
junctional epithelium onto the root surface with the concomitant loss of connective tissue and 
alveolar bone.6 Periodontitis can be considered to result from an imbalance between destruction 
and repair of periodontal tissues, triggered by bacteria present in periodontal pockets and possibly 
aggravated by systemic disorders. In fact, the bulk of tissue destruction is caused by host 
responses to oral bacteria: host cells (both resident and recruited from blood) release enzymes 
and cytokines in response to bacterial products. 83, 96Although periodontitis consists of a family of 
diseases, these diseases do share a common histopathology, manifest similar signs of disease and 
usually respond to conventional therapy. 
In a clinical and therapeutic point of view, periodontitis can be divided based on the extent or 
distribution in the mouth to localized and generalized, and based on the severity to 
slight/initial/mild, moderate and severe/advanced. Although there is no strict cut-off point for the 
division based on the extent, it has been recommended that the distribution of the disease is 
designated as: localized if less than 30 % of the sites are involved, and generalized if more. In 
case of the division based on severity, the amount of clinical attachment loss (CAL) is 
considered thereby designating the severity of periodontitis as: slight/initial/mild = 1 or 2 mm of 
CAL, moderate = 3 to 4 mm of CAL and severe/advanced = 5 mm or more of CAL.4  
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Periodontitis is one of the two major dental diseases, the other being dental caries, that affect 
human populations worldwide at high prevalence rates and that results in loss of teeth. Hence the 
prevention and treatment of periodontitis is of utmost importance in the field of dentistry. 
Prevention of periodontitis is achieved through promoting healthy lifestyles including good oral 
hygiene and reducing/eliminating risk factors.  
Contemporary periodontal therapy is directed towards controlling the infection, elimination of 
inflammation and restoring the lost supporting structures to their original form, function and 
consistency.60 Infection control can be achieved by proper initial phase periodontal therapy 
including through scaling and root planning, maintenance and antimicrobial therapy. Once the 
infection is controlled and etiologic factors are eliminated, the correction of the consequences 
caused by the disease is considered in order to achieve a better long-term prognosis of the 
involved teeth. This phase, called the corrective or surgical phase, includes various surgical 
procedures aimed at treatment of the unresolved periodontal pockets after the initial therapy, 
advancing loss of attachment, or need for regenerative procedures thereby trying to re-establish a 
favourable dental-periodontal relationship to improve the prognosis of the individual teeth and 
oral health in general. Finally, once the cause is controlled and the consequences have been 
corrected, recurrence of the disease should be avoided by planned careful follow-ups. This phase 
of the therapy is mainly supportive in nature and is called the maintenance or recall phase. 
Non-surgical therapy performed in the first phase may be sufficient to eliminate the signs and 
symptoms of mild periodontitis. However, many cases or sites with moderate to severe disease 
often continue to show signs of inflammation after a non-surgical approach. In such cases, 
surgical treatment is a necessity. The various surgical approaches implemented in the surgical 
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phase are open flap debridement (OFD), resective flap surgery, mucogingival surgery and 
reconstructive/regenerative surgery. The ultimate goal in periodontal therapy is the regeneration 
of periodontal tissues affected by diseases to their original form, function and consistency. 
Various techniques are attempted by periodontists in order to achieve periodontal regeneration 
with varying success. An ideal technique would be the one which is easier to perform and cost 
effective, which reduce the complexity involved in the treatment and which can predict 
favourable results.  
In the present study, we have evaluated the clinical outcome of a technique which is easier to 
perform, cost effective and imitates the most commonly used regenerative technique termed as 
guided tissue regeneration (GTR). 
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1.1 Epidemiology of periodontitis 
Periodontitis being one of the most common infectious diseases worldwide, its incidence and 
prevalence evoke a major interest among dental health professionals as well as the general 
public.  There have been a lot of studies done on the epidemiology of periodontitis. But the 
literature reveals a distinct lack of consensus and uniformity in the definition of periodontitis 
within epidemiological studies. There are also numerous differences in the methods used.  The 
consequence is that data from studies using differing case definitions and differing survey 
methods are not easily interpretable or comparable. Comparison of effect of risk factors (Odds 
Ratio, Relative Risk) between studies is hard.24   
A systematic review of the literature discovered that only 15 studies, out of 3472, gave a 
definition of periodontitis and indicated how it was measured. The criteria for a diagnosis of 
periodontitis ranged from 3 mm – 6 mm probing pocket depth and for clinical attachment loss (as 
an indicator of periodontitis) from 2 mm – 6 mm.146 The reviewed studies used measurements at 
different sites using different measurement tools. 146 Researchers have historically used an array 
of clinical signs and symptoms such as gingivitis, bleeding on probing, pocket depth, clinical 
attachment loss, radiographically assessed alveolar bone loss and even tooth loss, the ultimate 
endpoint of periodontal disease.17,89,93 Further complications are posed by the fact that in some 
studies multiple disease indicators such as pocket probing depth and clinical attachment level, 
both representing current pathology and cumulative tissue destruction respectively are used.27 
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1.1.1 The prevalence, extent and severity of periodontal diseases 
CPITN (Community Periodontal Index of Treatment Needs) was proposed by WHO in the late 
1970’s as an index to evaluate the periodontal treatment needs of populations.14 In the later 
years, CPITN was used most frequently over the world for epidemiologic studies although there 
are limitations like non-assessment of tooth mobility, furcation defects, clinical attachment loss 
etc. Initial field studies using CPITN provided informative results.2 In a large investigation of 
11,305 subjects in Hamburg, only 2.8 % were found to exhibit total periodontal health. 9 % had a 
CPI score of 1, 28 % had 2, 44 % had 3 and 16 percent had 4. Other studies using CPITN have 
provided similar results.3, 15, 43, 53, 75, 80 
The prevalence of periodontitis in adult populations has been measured in several studies by 
means of clinical assessment of periodontal attachment,16, 26, 88, 89, 91, 154, 155, 161 assessment of 
alveolar bone level,121, 145 or a combination of the two.122, 123 Some studies were cross-sectional, 
while others were designed as longitudinal or risk assessment studies.  
Table 1.1 summarises some important epidemiological studies of the distribution of periodontal 
disease in different populations around the world. Only major studies using probing depth and/or 
probing attachment levels are included. These major studies have presented characteristic 
patterns of periodontal diseases in various populations of different age groups. It is obvious that 
the criteria for defining disease cases are far from identical and make direct comparisons 
between studies difficult. However, it is evident that the prevalence of severe periodontitis is 
confined within a minority of a population studied. Our current understanding of periodontitis 
from findings of previous studies has led naturally to identification of factors that may play a role 
in determining disease initiation and progression on an individual or group level.  
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Table 1.1: Epidemiological studies of the distribution of periodontal disease in different 
populations around the world 
 
Author, date, 
country 
 
Methodology 
 
Results 
 
Baelum et al., 
1988,  Kenya.10 
 
Cross-sectional. 1131 Kenyan 
adults aged 15–65. LOA and 
PD at 4 sites per tooth of all 
teeth. Oral hygiene, tooth 
mobility. Examinations under 
natural light. 
 
The oral hygiene was poor with plaque on 
75-95 % and calculus on 10-85 % of the 
surfaces depending on age.  PD≥4 mm on 
<20 % of sites irrespective of age.                  
10-85 % of the surfaces had loss of 
attachment ≥1 mm.  Skewed distribution of 
CAL and PD≥4 mm and ≥7 mm.  
Highest extent of CAL at maxillary molars 
and mandibular incisors. 
 
Baelum et al., 
1997, China.12 
 
Longitudinal. 398 Chinese 
adults remained dentate at 
follow-up. Limited access to 
care. CAL and PD at 4 sites 
per tooth. Oral hygiene, tooth 
mobility. 
Extent of CAL≥3 mm and ≥4 mm in 10 
years was positively skewed.                                
21.8 % of sites lost 3+mm, 9 % 4+ mm. 
Highest extent of LOA at maxillary molars 
and mandibular incisors.                           
No significant difference in attachment loss 
with other populations from developed 
countries. 
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Beck et al., 1990, 
United States.16 
 
Cross-sectional. 690 
community-dwelling older 
adults aged 65 or over. Full 
mouth probing at two sites per 
tooth. 
 
Blacks- 78 % sites with attachment loss, 
average loss around 4 mm 
Whites- 65 % sites with attachment loss, 
average loss around 3.1 mm 
 
Brown, Oliver & 
Löe, 1990, United 
States.26 
 
Cross-sectional. 15,132 
employed United States adults 
aged 18–84. Half-mouth 
assessment of PD and GR at 
mesial and buccal sites. BOP. 
 
BOP: 44 % of subjects.  
PD 4–6 mm: 13.4 % of subjects or 0.6 sites 
per person and at 1.3 % of all sites. 
 
Mumghamba, 
Markkanen & 
Honkala, 1995, 
Tanzania.107 
 
Cross-sectional. 1764 subjects 
aged 3-84 years. GR and PD 
at buccal surface of ten index 
teeth. Plaque, calculus, 
gingival inflammation, oral 
hygiene behaviour, smoking. 
 
PD≥4 mm in 8 %; PD≥6 mm in 0.5 %.                                   
GR≥4 mm in 13 %.                 
Age, male sex, lower educational status, 
rural residence plaque and calculus, were 
significantly related to PD and GR in 
multivariate models. 
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Slade & Spencer, 
1995,        
Australia. 154 
 
 
Cross-sectional. Total 801 
subjects 60+ years of age, 
randomly selected in South 
Australia. Full mouth. PD and 
GR measured at three sites per 
tooth. 
 
 
CAL 4+mm at one or more sites in 89.1 % 
of subjects. 78.1 % sites per person had 
CAL of 2+ mm. Mean CAL: 3.09 mm.      
Highest mean CAL at maxillary molars.                                     
PD is higher than GR in maxilla and equal 
to GR in mandible. Men had more CAL 
than women 
Söder et al., 1994, 
Sweden.155 
 
 
Cross-sectional. 1,681 
subjects aged 31–40. Full 
mouth, 6 sites per tooth 
assessment for PD. 
 
4.9 % had 1 tooth, 6.7 % had 2–5 teeth, 2.4 
% had 6–9 teeth and 3.2 % had ≥10 teeth 
with PD≥5 mm. 
Calculus, smoking and frequency of dental 
visits were related to the number of teeth 
with PD≥5 mm. 
 
Yoneyama et al., 
1988, Japan.172 
 
Cross-sectional. Random 
sample of 319 subjects aged 
20– 79. Mean value, 
frequency distribution and 
percentile of PD and CAL at 
three sites per tooth. 
 
Practically all subjects had one or more 
sites with periodontal disease. Small 
subgroup aged 20–59 had advanced 
disease. Molar teeth expressed more 
disease. Severity of the disease increased 
with age. 
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1.1.2 Tooth and site specificity of periodontal attachment loss 
The classic study by Löe et al. (1978) examined different populations and observed different 
levels of CAL between teeth and sites among individuals irrespective of the populations studied. 
These differences were clearer with increased age. Mean clinical attachment loss was highest on 
maxillary molars and mandibular incisors. Buccal and interproximal sites appeared to have 
different rates of attachment loss as well.90 Some studies in developing countries have confirmed 
the unequal or specific distribution between sites on the teeth and between different teeth in a 
mouth. These studies have also reported highest loss of clinical attachment level on molars in the 
maxilla and incisors in the mandible.10, 12                                 
Several studies using the United States National Institute of Dental Research (NIDR) 
methodology in populations from developed countries had confirmed the site and tooth 
specificity of PD, GR and CAL. Slade and Spencer (1995) found among 60 and above years old 
South Australians the lowest mean CAL in mandibular incisors while confirming that maxillary 
molars have the highest mean CAL and differences between sites of the extent and severity 
scores of CAL.154 A study of the United States employed population (Brown, Oliver & Löe, 
1990) also had similar findings.26 A recent study in a younger population by Thomson, Hashim 
& Pack, which investigated site and tooth specificity of CAL and its components showed 
differences between site and teeth. They did not find higher extent and severity scores in 
mandibular incisors as compared to lower molars, in contrast to findings from developing 
populations.161 An important issue to consider when comparing between sites is the distribution 
of tooth loss by tooth type. Different tooth groups tend to be lost at different frequencies, thus 
making the comparison of periodontal destruction components sometimes difficult. Molar teeth, 
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which may accumulate more caries and/or periodontal disease, are more likely to be lost than 
other teeth. Therefore, a significant proportion of heavily diseased sites of those teeth may be 
already lost by extraction owing to deep destruction by caries. In this case, remaining teeth may 
be recorded as having more severe disease compared to missing teeth when it may not be true. A 
further question which arises is that some proportion of destruction recorded may not be true 
disease; it may be owing to other non-disease factors such as dehiscence of bone or habits 
causing gingival recession. The proportion of this destruction may not be equally distributed 
across the mouth. This issue may contribute to the unequal distribution of disease between teeth 
and sites. Previous findings suggested the site- and tooth-specificity of patterns of periodontal 
loss of attachment. However, no inferential testing of statistical significance between these 
differences had been done. Furthermore, some discrepancies in comparison between sites have 
been reported in findings of several studies referred to above. It is not clear yet whether these 
inconsistencies were owing to chance alone or to differences in methodologies, the discrepancies 
in distribution of tooth loss or to real differences between populations studied. This question 
needs to be further investigated. 
 
1.1.3 Distribution of periodontal diseases in developed and developing populations 
The previously held belief that higher prevalence and severity of periodontitis exist among 
populations of developing nations where living standards are lower and less access to health care 
services compared to that of developed nations has not been confirmed by most studies. Studies 
in the 1960s using composite indices had come to the conclusion that developing nations had 
poorer oral hygiene status and, consequently, more periodontitis.141, 142 That conclusion was a 
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result of the previously dominant concept of a necessary and sufficient role of oral hygiene in the 
disease initiation and progression and the scarcity of studies conducted among developing 
populations. However, Anerud et al. (1983), comparing groups of United States, Norwegian and 
Sri Lankan young adults found strikingly similar rates of periodontal breakdown, despite the last 
group having much poorer oral hygiene conditions.4 Furthermore, Baelum et al. (1996) raised 
very interesting issues by recalculating and comparing findings from several studies in various 
countries. Their meta-analysis had shown similarities in the disease patterns in six out of the 
eight samples, irrespective of oral hygiene conditions and levels of access to dental care.11 Loss 
of periodontal attachment data (mostly from developed countries) and the more superficial 
CPITN data from many developed and developing countries have presented similarities in the 
prevalence and severity of periodontitis.11, 13 There are few exceptions from some studies of Sri 
Lankan tea workers (Löe et al., 1978) and South Pacific Islands (Cutress, Powell & Ball, 
1982).44, 91 However, it is obvious that there are no clear differences in the prevalence of severe 
stages of periodontitis between developed and developing populations irrespective of 
methodologies and indices used. Clear differences are only apparent in poorer oral hygiene and 
greater calculus accumulation in even a young age group in populations of developing countries. 
Thus, the prevalence and severity of the disease can be considered far more similar between 
populations and are confined to small groups at high risk in each population. Different 
populations, however, may differ in the number of risk factors or in level of exposure to a 
particular risk factor or may have different resistance to risk factors. This area in periodontology 
requires further research. 
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1.2 Tissue destruction in periodontitis 
The periodontium consists of two hard tissues and two soft tissues. The hard tissues are alveolar 
bone and the cementum and the soft tissues are gingiva and periodontal ligament.  The structure 
and composition of periodontium are affected in many acquired and heritable diseases, most 
significantly periodontal diseases. The hallmarks of periodontal disease are bone loss, loss of 
connective tissue attachment to cementum and destruction of soft tissues. Periodontitis is a major 
cause of tooth loss in human beings.  
The pathogenesis of human periodontitis was first documented in detail by Page and Schroeder 
in 1976.118 The general principles and overall conclusions of their research are still valid. As 
time goes by, more and more researches were done trying to find out the exact mechanism of 
pathogenesis of periodontitis. In recent years, much has been added to the knowledge of the 
pathogenesis of the periodontal diseases, not only at the cellular, but also at the molecular and 
genetic levels. What this has done is that it offered new potential for prediction of risk and for 
treatment and control of the periodontal diseases. However, much of this field remains to be 
explored. 
The pathogenesis of periodontal disease involves the sequential activation of a great variety of 
components of the host immune response, primarily acting to defend periodontal tissues against 
bacterial aggression, but also functioning as mediators of tissue destruction. Pathogenic 
microorganisms can produce tissue destruction in mainly two ways: (i) by the direct pathological 
effects of bacteria and their products on the periodontium which induce cell death and tissue 
necrosis; and (ii) indirectly, through activation of inflammatory cells that can produce and 
release mediators that act on effectors, with potent pro-inflammatory and catabolic activity. 
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Some bacteria also interfere with the normal host defence mechanism by deactivating specific 
antibodies or inhibiting the action of phagocyte cells. The expression of the disease results from 
the interaction of host, microbiological agents, and environmental factors. Leukocytes play a 
critical role in the pathogenesis of the disease, producing different cytokines, chemokines, and 
other mediators, thus generating a host defence response, as well as inducing tissue inflammation 
and bone destruction.  Polymorphonuclear leukocytes (PMNs), which normally provide 
protection, can themselves contribute to tissue pathology. During the process of phagocytosis, 
these cells typically “spill” some of their enzyme content extracellularly during a process known 
as degranulation; some of these enzymes are capable of degrading the surrounding host tissues, 
namely collagen and basement membrane constituents, contributing to tissue damage. There is 
increasing evidence that the bulk of tissue destruction in established periodontitis lesions is a 
result of the mobilization of the host tissues via activation of monocytes, lymphocytes, 
fibroblasts, and other host cells. Engagement of these cellular elements by bacterial factors, in 
particular bacterial lipopolysaccharide (LPS), is thought to stimulate production of both catabolic 
cytokines like Interleukin 1 (IL-1), Interleukin 6 (IL-6), Interleukin 8 (IL-8), and Tumor necrosis 
factor alpha (TNF-α) and also of  inflammatory mediators including arachidonic acid metabolites 
such as prostaglandin E 2 (PGE 2). Such cytokines and inflammatory mediators in turn promote 
the release of tissue-derived enzymes, the matrix metalloproteinases, which are destructive to the 
extracellular matrix and bone.22, 116 The proportion of damage caused by direct effects of the 
bacteria and that caused by indirect host response mediated action has yet to be established. 
Although numerous bacteria can degrade tissue directly, like enzymatic breaking down of 
extracellular substances like collagen and even host cell membranes, Birkedal- Hansen et al 
suggested that host connective tissue is mainly degraded by the host.22 Thus, the loss of 
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connective tissue is a defence mechanism; the host attempts self-protection by the apical 
proliferation of junction epithelium, escaping from the toxic root surface to avoid lesion 
progression. 
In the article by Page and Schroeder, four phases of periodontal lesion progression in the cellular 
level were described: initial, early, established and advanced. The initial lesion was the response 
of gingival tissues within 2 to 4 days to a beginning accumulation of microbial plaque biofilm 
with a classic acute exudative vasculitis. This response, which includes loss of perivascular 
collagen, is comparable to that elicited in most other tissues subjected to acute injury and may be 
a consequence of the elaboration and release of chemotactic and antigenic substances by 
microbial plaque. Within 4 to 10 days, the early lesion develops. It is characterized by a dense 
infiltrate of lymphocytes and other mononuclear cells, pathologic alteration of fibroblasts, and 
continuing loss of the connective tissue substance. The structural features of the early lesion are 
consistent with those expected in some form of cellular hypersensitivity, and a mechanism of this 
kind may be important in the pathogenesis. The early lesion is followed by the established lesion 
which develops within 2 to 3 weeks and is distinguished by a predominance of plasma cells in 
the absence of significant bone loss. The established lesion, which is extremely widespread in 
humans and in animals, may remain stable for years or decades, or it may become converted into 
a progressive destructive lesion. In the advanced lesion, plasma cells continue to predominate 
although loss of the alveolar bone and periodontal ligament, and disruption of the tissue 
architecture with fibrosis are also important characteristics. The initial, early, and established 
lesions are sequential stages in gingivitis and they, rather than the advanced lesion which is 
manifest clinically as periodontitis, make up the major portion of inflammatory gingival and 
periodontal disease in humans. 
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1.3 Treatment of periodontitis 
 
According to the principles of lege artis, all practitioners of the dental profession are obliged to 
offer treatment based on the most current scientific and clinical knowledge available. The 
etiology of periodontitis is now well understood, and efficient methods for prevention, treatment, 
arrest, and control of periodontitis is developed based on that. Periodontal treatment requires 
long-range planning. Its value to the patient is measured in years of healthful functioning of the 
entire dentition. 
The aim of the periodontal therapy is to eliminate inflammation and the etiologic factors and to 
regenerate and restore the periodontal tissues affected by diseases to their original form, function 
and consistency.60 In order to achieve this, a periodontal therapeutic strategy is needed, planned 
in various phases. The first phase of treatment consists of controlling the etiological factors, 
thereby halting the further progression of the disease. This phase can be called as etiologic or 
hygienic phase and it includes patient motivation and education in matters of oral hygiene, 
elimination of supragingival and subgingival dental calculus and contaminated radicular 
cementum and modification/elimination of other plaque retentive features. The standard 
procedure employed for elimination of subgingival calculus and other unwanted contents of the 
periodontal pocket is commonly termed as scaling and root planing (SRP). Adjunct local or 
systemic antibiotics or other chemotherapeutic agents are also used widely.  After the first phase 
of treatment, once the cause of the disease is controlled, the correction of the consequences 
provoked by the disease is considered. This phase, called the corrective or surgical phase, 
includes various surgical procedures aimed at treatment of the unresolved periodontal pockets, 
advancing loss of attachment, or need for regenerative procedures thereby trying to re-establish a 
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favourable dental-periodontal relationship to improve the prognosis of the individual teeth and 
oral health in general. Finally, once the cause is controlled and the consequences have been 
corrected, recurrence of the disease should be avoided. This implies the third phase of the 
periodontal treatment, also called the maintenance or recall or supportive phase. 
1.3.1 Non-surgical therapy  
Non-surgical therapy includes both mechanical and chemotherapeutic approaches to minimise or 
eliminate the primary etiology of periodontitis, the microbial biofilm. Mechanical therapy 
consists of debridement of the radicular surfaces by the meticulous use of hand or power-driven 
scalers to remove dental plaque, endotoxins, calculus and other retentive features. The term 
mechanical therapy refers to supragingival and subgingival scaling as well as root planing. 
Chemotherapeutic approaches include topical application of antiseptics or sustained-release local 
drug delivery systems and the use of systemic antibiotics.  
Scaling and root planing (SRP) is one of the most commonly utilized procedures for the 
treatment of periodontal diseases. Scaling and root planning allow reduction in pocket depth 
mainly by new connective tissue or epithelial attachment; with a probable gain in clinical 
attachment level. Periodontal literature is sated with studies showing the treatment of 
periodontitis by scaling and root planing results in reductions of probing depths.9, 35, 67, 68 The 
decrease in probing depth is caused partly by the shrinkage of the pocket soft tissue wall 
manifested as recession of the gingival margin which results from a decrease in soft tissue 
inflammation; and partly from the gain in clinical attachment.9, 35, 67, 68 In a thorough evidence-
based review published in 1996, Cobb calculated the mean probing depth reduction and gain of 
clinical attachment that can be achieved with root planing at sites that initially were 4 to 6 mm in 
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depth and 7 mm or greater in depth. He reported mean pocket depth reductions of 1.29 mm and 
2.16 mm, respectively, and mean gains of clinical attachment of 0.55 mm and 1.29 mm, 
respectively. 
Most of the beneficial effects of SRP appeared to occur within the first 3 months with mean 
attachment levels and pocket depths remaining relatively unchanged at later time points.120 An 
increase of clinical attachment refers to new connective-tissue attachment (that is, new 
periodontal fibres inserting into the cementum) or formation of a so-called long junctional 
epithelium (repair). Usually, the latter occurs. 
 
1.3.2 Surgical therapy 
Non-surgical therapy performed in the first phase may be sufficient to eliminate the signs and 
symptoms of mild periodontitis. However, cases or sites with moderate to severe disease often 
continue to show signs of inflammation after a non-surgical approach. In such cases, surgical 
treatment is a necessity. Many different surgical techniques and materials have been reported in 
the literature to successfully treat periodontal intrabony defects. The various surgical approaches 
implemented in the surgical phase are open flap debridement (OFD), resective flap surgery, 
mucogingival surgery and reconstructive/regenerative surgery. An ideal technique would be the 
one which could achieve periodontal regeneration and which is easier to perform and cost 
effective.  
 As mentioned earlier, the ultimate goal in periodontal therapy is the regeneration of periodontal 
tissues affected by diseases to their original form, function and consistency. In teeth in which 
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continued function requires additional periodontal support, optimal treatment involves not only 
controlling periodontal infection, but also regeneration of the lost periodontium.  
The current techniques in the treatment of periodontitis aimed at periodontal regeneration include 
open flap debridement- OFD,47, 55 74, 134 the use of bone grafting materials,25, 129, 133, 135, 140, 174, 177 
Guided tissue regeneration – GTR,37, 40, 41, 46, 51, 85, 97, 108, 112 and also the use of certain biologic 
modifiers like Enamel matrix derivatives – EMD49, 149 or various other growth factors (i.e. 
Platelet Derived Growth Factor - PDGF, Insulin like Growth Factor – IGF, Transforming 
Growth Factor-β (TGF-β) including  Bone Morphogenetic Proteins – BMPs).77, 92, 117, 130, 143  
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1.4 Periodontal wound healing  
The basic events of wound healing are the same regardless of the location of the body. Thus 
periodontal wound healing after an injury or a surgery also involves three overlapping phases 
that are independent.34 The phases can be called as inflammatory phase, proliferative/granulation 
phase and remodelling/maturation phase. Traumatic or surgical injury causes haemorrhage and 
extravasation of blood, and a blood clot is formed. The blood coagulation process and activated 
complement pathway generate many polypeptide mediators, and the blood clot serves as a 
provisional matrix for the migration of inflammatory cells. In the proliferative phase, re-
epithelialisation occurs, along with angiogenesis and activation of various components of 
extracellular matrix and the clot is replaced by a granulation tissue. During the remodelling 
phase, the granulation tissue matrix is replaced with fresh connective tissue. A fibrous scar 
replaces the wound when regeneration is not possible.34, 153  
Periodontal wound healing is regarded as the most complex healing process in the human body.98 
It is mainly because of the different types of tissues involved and that the healing should take 
place in an open system which is continuously contaminated with bacteria and their products. 
Therefore, the healing results following periodontal therapy can be quite variable. In the site of 
periodontal healing, we have four situations which might occur. First, the epithelium will try to 
migrate from the wound margin down to the base of the sulcus. If this occurs, the 
reestablishment of the pocket or in the best scenario, long junctional epithelium will be 
established. Secondly, the connective tissue will try to grow into the area of the defect. If this 
occurs, the end result will be external resorption at the connective tissue-root interface. Thirdly, 
if the bone cells are allowed to repopulate the area of defect, ankylosis or resorption will occur at 
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the junction of bone to tooth interface. Karring et al in 1980 demonstrated this in beagle dogs, of 
which when the roots were extracted and transplanted into a surgically created alveolar bone in 
the edentulous part of a jaw, ankylosis and root resorption occur.78 Finally, the cells of 
periodontal ligament, if allowed to repopulate the root surface, the regeneration can be 
established. Nyman et al in 1982 showed in a study in monkey with the use of millipore filter to 
exclude the epithelium and the gingival connective tissue. After three months, the histological 
specimen demonstrated new attachment, new cementum, and new bone.113 He further confirmed 
this result with the follow up study on a root surface in human using the principle of GTR. A 
block biopsy of a lower central incisor at three months after surgery showed new cementum and 
with inserting collagen fibres extending five millimetres coronally from the apical level of root 
planning.115 Melcher in 1976 reported these four tissue compartments in the periodontium and 
that each of these tissues was capable of producing a unique cell phenotype, and that the type of 
healing following periodontal therapy depended on the phenotype of the cells which first 
repopulated the root surface.100 
In short, healing of periodontal wounds after periodontal therapy can be achieved either by repair 
or by regeneration. Repair involves only the restoration of continuity in the wound or defect area 
without regeneration of the originally intact tissues’ form and function: e.g. long junctional 
epithelial attachment. Regeneration of supporting tooth structures is a huge step up in managing 
advanced periodontal disease and preventing tooth loss. Like other treatment options, it is not a 
panacea for all patients affected by periodontitis, but research gives us enough evidence to 
support the use of regenerative therapies in periodontics. 
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1.5 Guided Tissue Regeneration: Principles and evolution 
 
The ultimate goal of periodontal therapy is predictably regeneration of the periodontal tissues 
destroyed by peridontitis. Regeneration should be distinguished from repair. Regeneration is 
defined as the type of healing which completely replicates the original architecture and function 
of a part. It involves the formation of a new cementum, periodontal ligament, and alveolar bone. 
Repair, on the other hand, is merely a replacement of loss apparatus with scar tissue which does 
not completely restore the architecture or the function of the part replaced. The end product of 
repair is the establishment of long junctional epithelium attachment at the tooth-tissue interface. 
Traditional therapeutic modalities usually failed to predictably regenerate the periodontal tissue 
lost due to disease process. The principle of guided tissue regeneration (GTR) can be applied and 
may result in restitution of the functional periodontal apparatus (new cementum, periodontal 
ligament, and alveolar bone). Procedures which relies heavily in the principle of GTR involves 
those whose end result is the complete regeneration of periodontal structures which were lost due 
to periodontal disease, those whose objective is the ridge augmentation to allow proper 
placement of osseointegrated implant, and also the procedures which are utilized in treatment of 
furcation and recession defects. 
GTR procedures attempt to achieve periodontal regeneration through biologic principles of 
differential tissue response. The cells of periodontal ligament if allowed to repopulate the root 
surface by preventing the faster proliferating epithelial cells and other unwanted cells in to the 
periodontal bony defect, regeneration can be established. The principle of GTR thus involves the 
use of a physiological barrier which is placed over the denuded lesions in such a way that all 
periodontal tissue except the periodontal ligament cells and the alveolar bone are prevented from 
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reaching contact with the root. The cells of periodontal ligaments are the only ones which seem 
to have the capacity to form new attachment. Cells of periodontal ligament migrates and 
differentiate faster than those of bone, thus even though bone cells were allowed to migrate to 
the area along with the cells of PDL, we would expect the cells of PDL will repopulate along the 
root surface. 
The use of a barrier has first been reported by Younger in the Dental Cosmos of 1904, in which a 
Japanese paper saturated with liquid celluloid was used to form a protecting wall over the roots 
and the edge of the gingiva.173 Prichard in 1957 further stated that cells that are necessary for the 
genesis of periodontal ligament, cementum, and alveolar bone are available in the area that 
borders the bony deformity.128 Melcher in 1976 classified the four tissue types which will 
repopulate the root surface as described previously.100 Further investigations in the 1970’s and 
80’s supported Melcher’s concept. Caton et al examined healing following four different 
modalities of periodontal treatment (scaling and root planing, modified Widman flap with 
debridement alone or in combination of autogenous or synthetic bone graft). The end results 
demonstrated the establishment of long junctional epithelium between the gingival connective 
tissue and the root surface upon healing.31, 32, 33 This finding supported other similar studies that 
conventional nonsurgical and surgical periodontal therapies usually resulted in repair rather than 
regeneration. 
The effects of epithelial exclusion are further investigated by Nyman in 1980. When root was 
allowed to contact alveolar bone, ankylosis and root resorption occurred. When root was allowed 
to contact the gingival connective tissue and the root surface had been denuded of periodontal 
fibre, the root resorption occurred.114 These observations suggested that exclusion of gingival 
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epithelium alone does not promote periodontal regeneration. His further study with the Millipore 
filter in 1982 reported that the periodontal ligament cells has a considerable potential for 
periodontal regeneration, and that this potential is manifested only when the gingival epithelium 
and connective tissues are excluded from the periodontal wound.113 He further followed up on 
the human study on the selected mandibular incisor. Again, histological evaluation revealed new 
cementum with inserting collagen fibres extending 7 mm from the apical level of root planing in 
a coronal direction.115  
In 1986, Gottlow et al presented a case report of 12 periodontally involved teeth from 10 patients 
treated using this biologic principle. Eleven of these teeth formed the experimental group and 
were treated by flap elevation, granulation tissue debridement, scaling and root planing followed 
by placement of ePTFE barrier (Goretex membrane). The remaining tooth was also surgically 
treated but without the placement of barrier as the controls. Clinical results from re-entry 
indicated significant gain in clinical attachment and probing depth reduction, as well as an 
apparent bone fill in some of the previously presented osseous defects. Histological observations 
disclosed a substantial amount of periodontal regeneration in all the teeth treated with the 
barrier.66 These findings demonstrated that periodontal regeneration could be predictably 
obtained in humans by placing the physical barrier, which selectively excludes gingival 
epithelium and connective tissue and favours periodontal ligament repopulation of the root 
surface. 
The cellular process involved in the development of the periodontium and in wound healing must 
be understood in order to comprehend the regeneration concept in periodontal defects. The major 
type of cell in the periodontal ligament is the fibroblast. Fibroblasts are located throughout the 
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connective tissues of the body, where their role is to maintain the extracellular matrix substance. 
The periodontal fibroblast is capable of extensive protein and collagen synthesis and that it 
responds well to the molecular mediators during the process of wound healing. Fibroblast 
apparently has the potential to develop into different types of cells during wound healing, 
depending on the molecular mediator that stimulates it. The precursor cells of the periodontal 
ligament, in this case the fibroblast can differentiate into osteoblasts, or cementoblasts, 
depending on their position. Cell migration in the periodontal ligament seems to occur starting at 
the bone interface and continuing along the collagen fibres. There must be a mechanism which 
selectively activates bone precursor cells to repopulate the area and establish a new tissue exactly 
like the originating tissue, with each type of cell in its proper position. Specific cellular types that 
repopulate the wound defect will determine the form and type of tissue that will be created. The 
proliferation of the proper type of cells in their proper position may be regulated via molecular 
growth factors which are thought to be responsible for specifically stimulating the proliferation 
of cementum, periodontal ligament, and bone cells. The ultimate goal of GTR is to use a 
mechanical barrier to provide the environment necessary for the body to utilize its natural 
healing potential and to regenerate lost and absent tissue. Ultimately, the efficacy of periodontal 
membranes in conjunction with wound healing is the result of a combination of different 
mechanisms- mechanical, cellular, and molecular.  
The chief clinical indications for the use of GTR are the class II furcation defects, two or three 
walled vertical, interproximal, and circumferential intrabony periodontal defects. Class III 
furcation may be treated with GTR but with less predictability of success. Other clinical 
indication of GTR are the ridge augmentation (can also be referred to as guided bone 
 41 
 
regeneration), and the treatment of gingival recession. Sites which may be at risk for post 
surgical recession are best treated with nonresorbable barriers, since barrier exposure may 
accelerate resorbable barrier degradation. Bone graft may be used in combination with GTR for 
the supporting purpose to prevent the collapse of the membrane. Success of GTR treatment relies 
heavily on the ability to stabilize the blood clot. Blood clot stabilization is the major prerequisite 
for the regeneration to evolve. Wikesjö has shown without the blood clot (with the use of heparin 
to dissolve the clot on root surface), the regeneration failed to occur.170 Other factors which aided 
in successful GTR technique are oral hygiene, adequate initial hygienic therapy, proper flap 
selection and management, adequate debridement to completely remove all granulation and soft 
tissue at the treated site, the decortication of the bony defect underneath the membrane to 
stimulate the formation of a blood clot, adequate adaptation of membrane to prevent epithelium 
to migrate underneath the membrane, adequate debridement to denude the bone of the defect site, 
adequate size and shape barrier chosen (extending 2-3 mm pass the border of the defect), and 
finally, complete coverage the membrane underneath the flap upon suturing. Sutures may be 
removed after 7-10 days. If PTFE sutures are used, they may be allowed to remain for a longer 
period of time in order to aid in flap adaptation since this type of suture does not cause wicking 
and trapping of bacteria. If the barrier is nonresorbable, it is usually removed approximately 4-8 
weeks. The most important period of cell migration and proliferation are the first 30 days. If the 
membrane can be maintained underneath the flap for this initial period, we can achieve closely or 
maximal amount of regeneration. In short, primary wound closure to ensure undisturbed and 
uninterrupted wound healing, angiogenesis to provide necessary blood supply and 
undifferentiated mesenchymal cells, space maintenance/creation to facilitate adequate space for 
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bone ingrowth, and stability of wound to induce blood clot formation and uneventful healing 
events are desirable characteristics to achieve in any GTR procedure.162, 168  
1.5.1 Nonresorbable barriers 
Nonresorbable membranes retain their build and form in the tissues, requiring a second surgical 
procedure for removal, thus adding to the trauma of the periodontal tissues and to patient 
discomfort, as well as raising the costs and duration of therapy. The first non-resorbable 
membranes approved for clinical use were made of expanded polytetrafluorethylene (ePTFE, 
Gore-Tex®). PTFE is a fluorocarbon polymer with exceptional inertness and biocompatibility, 
prevents tissue ingrowth and does not elicit foreign-body response after implantation, but is 
nonporous.165 Expanded PTFE is chemically identical, causes minimal inflammatory reaction in 
different tissues, allows tissue ingrowth and has been used in vascular surgery for several 
decades.29, 48, 52 It is manufactured when PTFE is subjected to high tensile stress, forming porous 
microstructure of solid nodes and fibrils. Gore-Tex® ePTFE membrane consists of two parts. 
First, an open microstructure collar which promotes connective tissue ingrowth, positioned 
coronally, and prevents apical epithelial migration and ensures wound stability. This membrane 
part is 1 mm thick and 90 % porous.147 The other part is occlusive membrane 0.15 mm thick and 
30 % porous, serving as a space provider for regeneration, which possesses structural stability 
and serves as a barrier towards the gingival flap.76, 152 Human histological samples have indicated 
that ePTFE membranes can lead to significant periodontal regeneration after a 3 months healing 
period.66 Six months after insertion of ePTFE membrane new cementum with inserting fibres 
was demonstrated.38 Effectiveness of ePTFE membranes was investigated in numerous clinical 
studies. Membrane insertion can cause minor complications such as pain, purulence and 
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swelling, with an incidence somewhat higher than that reported for conventional periodontal 
surgery.109  
Giampaolo Pini Prato and co-workers in 1992 reported the four year follow up results of a 
clinical trial of which guided tissue regeneration versus mucogingival root coverage surgery 
were used in the treatment of human buccal recession. The result showed that average reduction 
in the recession was similar in the two groups while probing depth reduction and clinical 
attachment level were greater in the GTR group.125 A study by Roccuzzo and Buser 
demonstrated a mean root coverage of 84 % when buccal gingival recessions were treated with 
e-PTFE membranes and miniscrews.138 
The Gore-Tex® ePTFE membrane has been modified by incorporation of titanium 
reinforcements, set between two ePTFE layers, resulting in heightened mechanical strength and 
better space maintenance.38, 71, 152 Animal studies revealed clinically relevant cementum and bone 
regeneration 2 months after insertion,152, 171 and clinical studies found no difference compared to 
non-modified membranes.18 Titanium reinforcement membranes also have their application in 
guided bone regeneration procedures (GBR) aimed at augmentation of toothless alveolar bone, in 
cases where implants are planned and insufficient alveolar bone mass is present. Membrane 
made from dense non-porous PTFE-a (TefGen-FD®) was tested on rat calvarial defects showing 
results similar to ePTFE membrane application, but with limited tissue integration.42 
In the literature use of other nonresorbable materials for GTR membranes is described, like 
several case-reports of rubber-dam39, 144 and glass ionomer.1 Although the number of 
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investigations is limited, it seems that these materials do not fulfil all the mentioned requirements 
for GTR procedures.  
1.5.2 Resorbable barriers 
Resorbable membranes do not require additional surgery, reduce patient discomfort and costs, 
and eliminate potential surgical complications. Resorbable barriers can be natural or synthetic. 
Collagen is the most commonly used natural barrier membrane. Collagen is acquired from 
animal skin, tendons, intestines or pericardium. Locci and co-workers (1997) compared collagen 
and PTFE biocompatibility and showed that PTFE inhibited gingival fibroblasts DNA synthesis, 
while collagen membrane stimulated proliferation of these cells. Besides, PTFE membrane 
significantly reduced extracellular matrix synthesis, so results stand in favour of collagen 
biocompatibility.87 Wang and co-workers (2002) showed higher adherence of osteoblasts to 
surfaces of collagen than non-collagen membranes.167 Meta-analysis of clinical GTR 
investigations showed equal effectiveness to nonresorbable.50 The collagen membrane appears to 
be useful and beneficial material for regenerative therapy in the treatment of periodontal defects. 
Other natural products tested for GTR without success were dura matter,61, 176 oxydized 
cellulose,58, 86 and laminar bone.148 
 
Synthetic resorbable materials are usually organic aliphatic thermoplastic polymers. The 
materials most commonly used are poly-α-hydroxy acids, which include polylactic-polyglycolic 
acid and their copolymers. One of the advantages of polyhydroxy acids is hydrolysis to final 
products water and carbon dioxide. Carbon dioxide can cause tissue irritation due to the 
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formation of carbonic acid thereby creating an acidic environment. Degradation time can vary, 
lengthened through the addition of lactides or glycols.21, 94 
 
A double-layered absorbable membrane (Guidor®) made of polylactic acid and a citric acid ester 
acetyl tributylcitrate was the first to appear on the market. The design of Guidor is a multilayer 
matrix, which facilitates the ingrowth of gingival connective tissue from the inner aspect of the 
periodontal flap. This ingrowth is assumed to retard and prevent the apical downgrowth of 
gingival epithelium. Resorbable barrier provided the advantage of eliminating the second surgery 
to retrieve the undegraded barrier membrane. This second surgery may disrupt initial healing and 
limit the overall attachment gain. The use of the membrane in single site recession eliminated the 
problems associated with conventional grafting which includes colour and tissue texture 
alteration and patient discomfort due donor site on the palate. In a survey by Roccuzzo in 1996, 
all patients preferred the Guidor treatment for better comfort.139 Patients clearly preferred the 
single site GTR technique since they can avoid the palatal wound.  
Gottlow et al in 1994 evaluated the use of resorbable barrier in recession type and interproximal 
defects in nonhuman primates. Clinical healing following surgery progressed with minimal or no 
gingival inflammation. Histological evaluation demonstrated the new cementum with inserting 
periodontal ligament fibres extending to the coronal border of barrier together with new bone 
formation. After 6 months, the barrier was completely resorbed.65  
The following years witnessed the publications of further research works by Polson et al and   
Genon et al. Polson and co-workers were involved in the multicentered study of Guided Tissue 
Regeneration in human furcation defects after using a biodegradable barrier. A total of 29 
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patients with class II furcation defects were treated using polylactic acid biodegradable barrier. 
At twelve month post surgery, there was clinically and statistically significant improvement in 
mean pocket depth reduction (2.2 mm) and attachment level vertical gain (1.7 mm), and 
attachment level horizontal gain (2.5 mm). These results indicated favourable clinical 
regenerative outcomes after using this barrier material in class II furcation defects in humans.127 
Genon et al presented data from 16 cases in which the Guidor matrix barrier was used in 
conjunction with the coronally position flap to treat the recession defect. Gingival recession was 
reduced on average by 3.7mm with gingiva up to or within 1mm of cemento-enamel junction in 
9 of 16 patients. Clinical attachment level improved; a mean attachment gain of 3.9 mm was 
attained.62 
The use of polyurethane for membrane production has been tested as wel.58, 151, 169 Polyurethanes 
are organic polymers containing urethane group -NH-CO-O-, materials with diverse properties. 
Polyether urethanes are degraded through enzymatic and oxidative degradation.124, 131 The 
degradation process although is extremely slow.  
Black et al in 1994 compared the clinical response of Biomend collagen and ePTFE membranes 
in the treatment of class II furcation defects in 13 patients. Six months post treatment, the mean 
vertical probing depth reduction was 1.4 mm for the collagen barrier sites versus 1.1 mm for the 
nonresorbable barrier sites. The decrease of horizontal probing depth was 1.5mm and 0.8 mm for 
the resorbable and nonresorbable barrier treated sites, respectively. The author reported that the 
resorbable collagen barrier was found to be equivalent to the nonresorbable barrier in the clinical 
resolution of class II furcation defects.23 
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In conclusion, the principle of GTR lies in the establishment of the cells of periodontal ligament 
to selectively repopulate the root surface. Clot establishment and stabilization, site selection, 
epithelial cell exclusion, space provision, neovascularisation, and complete gingival coverage are 
favourable characteristics in any GTR procedure. In the future, GTR can be combined with the 
use of biological growth factors that allowed for selectively control the type of cells proliferated 
from the fibroblast precursor. 
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1.6 Bone grafting and the types of bone graft materials 
The combination of graft materials with guided tissue regeneration is a proven modality of 
therapy for the treatment of intrabony defects and Class 2 furcation invasions. The use of bone 
grafts for reconstructing intra-osseous defects produced by periodontal disease dates back to 
Hegedus in 1923.73 It was then revived in 1965 by Nabers and O'Leary.110 Now, with the 
introduction of advanced bone grafting techniques and the use of sophisticated bone replacement 
graft materials, it is possible to increase the volume, width, and height of bone in deficient areas 
to regenerate the tissues supporting affected teeth and also to permit the placement of implants in 
their ideal positions and angulations.                                                                                                                           
 
A bone graft can aid in bone regeneration by three different methods, which include (i) 
osteogenesis, (ii) osteoconduction, and (iii) osteoinduction.  Osteogenesis is the formation of 
new bone by the cells contained within the graft material. Osteoinduction is a chemical process 
in which molecules contained within the graft (bone morphogenetic proteins) convert the 
patient's cells into cells that are capable of forming bone. Osteoconduction is a physical effect by 
which the matrix of the graft forms a scaffold on which cells in the recipient site are able to form 
new bone.111 
 
1.6.1 Classification 
Bone replacement grafts can be broadly classified into human bone and bone substitutes. This 
can be further classified into autografts, allografts, xenografts, and alloplasts.111 
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I) Human bone 
Autografts or autogenous grafts 
      - Extraoral 
      - Intraoral 
Allografts or allogenic grafts  
      - Fresh frozen bone 
      - Freeze-dried bone allografts (FDBA) 
      - Demineralized freeze-dried bone allografts (DFDBA) 
II) Bone substitutes 
 Xenografts or xenogenic grafts 
      - Bovine-derived hydroxyapatite 
      - Coralline calcium carbonate 
Alloplasts or alloplastic grafts  
      - Absorbable 
      - Nonabsorbable 
 
Historically, autografts were the first bone replacement grafts to be reported for periodontal 
applications. Allogenic freeze-dried bone was introduced to periodontics in the early 1970's, 
while demineralized allogenic freeze-dried bone gained wider application in the late 1980's. The 
introduction of xenografts and alloplasts for periodontal use occurred during the same time.111 
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1.6.1.1 Autografts 
Autogenous grafts are harvested from the patient, from intraoral sites (such as the maxillary 
tuberosity of a healing extraction site) and extraoral sites (such as the iliac crests, ribs, cranium 
and tibial metaphyses).59, 150 The decision to use autogenous grafts necessitates consideration of 
the donor site, procurement technique and handling or processing of the harvested material. 
Autogenous bone can be harvested intraorally, with or without processing, to yield graft 
materials of different forms, including cortical chips, osseous coagulum and bone blend. Many 
investigators have reported on the clinically successful use of intraoral autogenous grafts in the 
treatment of intrabony defects.30, 81, 103 Regardless of the intraoral donor site, autografts yield 
regenerative responses superior to that of surgical debridement alone. Extraoral autografts such 
as those obtained from iliac crests have demonstrated great potential for supporting new bone 
growth, including clinical and histological evidence of crestal bone apposition and periodontal 
ligament formation. Schallhorn & Hiatt considered the fill of crestal facial and furcation defects 
to be more clinically predictable using iliac autografts than with intraoral cancellous bone.150 
Autogenous grafts are non-immunogenic and contain osteoblasts and osteoprogenitor stem cells, 
which are capable of proliferating. These grafts, therefore, are osteoinductive. There are 
limitations to obtaining autogenous grafts, however, such as insufficient oral sites, the 
requirement for a second surgical site and morbidity at the donor site.140 
1.6.1.2 Allografts 
Allografts, bone grafts that are harvested from one person for transplantation in another, are used 
widely. There are three main divisions: frozen, freeze-dried and freeze-dried demineralized.                                                                                                                           
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The possibility of disease transfer, antigenicity and the need for extensive cross-matching has 
disallowed the use of fresh frozen bone in modern periodontics. The evidence that freeze-drying 
markedly reduces the antigenicity and other health risks associated with fresh frozen bone, as 
well as the favourable results obtained in the field trials with freeze-dried bone allografts, have 
led to the extensive use of freeze-dried bone allografts in the treatment of periodontal osseous 
defects.54, 105 The use of cortical bone is recommended rather than cancellous bone allografts 
since cancellous bone is more antigenic and there is more bone matrix and consequently more 
osteoinductive components in cortical bone. Freeze-dried bone allograft is regarded as 
osteoconductive.64 The blockade of the effect of bone growth stimulating factors sequestered in 
bone matrix, like the bone morphogenic proteins, led to the development of demineralised 
allografts. Experimental animal studies have shown that demineralised freeze-dried bone 
allograft has osteogenic potential.101, 102                                                                                                       
The advantages of using allografts are that the material is available in large quantities and there 
is no donor site within the patient. The disadvantages are that the process for preparing the graft 
(that is, freeze-drying and irradiating) decreases the material’s integrity and osteogenic potential, 
and the immunological response to it may diminish its incorporation into the recipient bone. A 
major concern with allografts in general is the potential for disease transfer, particularly viral 
transmission and more particularly HIV.104 Also, there is a need for extensive cross-matching to 
decrease the likelihood of both graft rejection and disease transmission. 
1.6.1.3 Xenografts 
Xenografts are made of naturally derived deproteinised cancellous bone from another species 
(such as bovine or porcine bone). The risk of transmission of diseases such as bovine spongiform 
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encephalopathy is negligible because the bone’s organic component is extracted. After the 
extraction of the organic components, the remaining inorganic structure provides a natural 
architectural matrix as well as an excellent source of calcium. The inorganic material also 
maintains the physical dimension of the augmentation during the remodelling phases. Bovine-
derived hydroxyapatite bone replacement grafts increase the available surface area that can act as 
an osteoconductive scaffold due to their porosity and have a mineral content comparable to that 
of human bone, allowing then to integrate with the host bone. These grafts are prepared by 
chemical or low-heat extraction of the organic component from the bovine bone. Examples of 
commercially available bovine-derived bone replacement grafts are Bio-Oss® (Osteohealth Co., 
Shirley, NY) and Osteograf/N® (CeraMed Dental, LLC, Lakewood, CO).                                                                                                                                 
Coralline calcium carbonate graft is obtained from a natural coral, genus Porites. It is hugely 
porous similar to that of spongy bone and so it provides a large surface area for resorption and 
replacement by bone.69, 175 An example for such type of grafts is Biocoral® (Inoteb, Saint 
Gonnery, France). Biocoral has a high osteoconductive potential because no fibrous 
encapsulation has been reported.                                                               
The main advantages of xenografts are that they are osteoconductive and readily available. A 
major disadvantage of bovine-derived grafts is due to the fact that it can cause disease 
transmission, which was evident in the case of bovine spongiform encephalopathy reported in 
Great Britain.111 
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1.6.1.4 Alloplasts 
The alloplastic grafts or synthetic bone graft substitutes as yet offer only a part solution to the 
management of localized bone loss. They possess some of the desired mechanical qualities of 
bone as well as osteoconductive properties but are largely reliant on viable periosteum/bone for 
their success. They primarily function as defect fillers. Ideally synthetic bone graft substitutes 
should be biocompatible, show minimal fibrotic reaction, undergo remodelling, should have a 
similar strength and elasticity to that of the bone being replaced, thereby supporting the new 
bone formation. They do not induce adverse local tissue reaction, immunogenicity or systemic 
toxicity.  They can be classified, by their ability to be bioabsorbed, into absorbable and non-
absorbable.  
The absorbable materials include alpha and beta tricalcium phosphate, non-sintered 
hydroxyapatite, and calcium sulphate. The non-absorbable materials include sintered 
hydroxyapatite, bioglass and HTRTM polymer.                                                                                                                                              
Bioceramic alloplasts are comprised mainly of calcium phosphate, with the proportion of 
calcium and phosphate similar to bone. The two most widely used forms are tricalcium 
phosphate and hydroxyapatite.                                                                                                                   
Tricalcium phosphate is a porous form of calcium phosphate. Alpha and beta tricalcium 
phosphate are produced similarly, although they display different resorption properties. The 
crystal structure of alpha tricalcium phosphate is monoclinic and consists of columns of cations 
while the beta tricalcium phosphate has a rhombohedral structure. The former is formed by 
heating the later above 1180 °C and quenching in air to retain its structure.63 Alpha form is less 
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stable than beta and forms the stiffer material calcium-deficient hydroxyapatite when mixed with 
water.160 The most commonly used form is beta tricalcium phosphate. It is one of the earliest 
calcium compounds to be used as a bone graft substitute. Structurally porous beta tricalcium 
phosphate has a compressive strength and tensile strength similar to that of cancellous bone. It 
undergoes resorption over a 6-18 month period. Unfortunately, the replacement of beta 
tricalcium phosphate by bone does not occur in an equitable way. That is, there is always less 
bone volume produced than the volume of the graft material resorbed. For this reason, the 
clinical use of beta tricalcium phosphate has been rather as an adjunctive with other less 
resorbable bone graft substitutes or as an expander for autogenous bone graft. The examples of 
commercially available beta tricalcium phosphate graft material are SynthograftTM (Bicon, 
Boston MA, USA) and Cerasorb® (Curasan Pharma GmbH, Kleinostheim, Germany).                                                                                                                    
The next calcium phosphate preparation to become available was the synthetic hydroxyapatite in 
the 1970's. It is available in resorbable and non-resorbable forms. Whether synthetic 
hydroxyapatite is resorbable or non-resorbable depends on the temperature at which it is 
prepared. High-temperature preparation (sintering) of hydroxyapatite results in a nonresorbable, 
nonporous, dense material.82 Dense non-resorbable hydroxyapatite grafts are osteophilic, 
osteoconductive and act primarily as inert biocompatible bone defect fillers. Histologically, new 
attachment is not achieved but yield a more stable clinical improvement than with open flap 
debridement alone in the treatment of periodontal osseous defects.57, 174, 177 The resorbable form 
is processed at a low temperature. As it resorbs, a readily available source of calcium becomes 
available in sites that have osteogenic potential.136 Its reported advantage is the slow resorption 
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rate, allowing it to act as a mineral reservoir at the same time acting as a scaffold for bone 
replacement.166 It is marketed in different trade names like Osteogen® (Impladent, NY, USA).  
Calcium sulphate or plaster of Paris was first documented as being used for fracture treatment by 
the Arabs in the 10th century, who would surround the affected limb in a tub of plaster. In 1852 a 
Dutch army surgeon named Mathysen incorporated plaster into a bandageable form, which we 
are familiar today.106 Calcium sulphate is thought to act as an osteoconductive matrix for the 
ingrowth of blood vessels and associated fibrogenic and osteogenic cells. For this to occur it is 
critically important that the implanted calcium sulphate is adjacent to viable periosteum or 
endosteum.36 Over a period of 5–7 weeks, calcium sulphate is reabsorbed by a process of 
dissolution.20 Currently, a medical grade of calcium sulphate impregnated with tobramycin is 
commercially available (Osteoset®; Wright Medical Technology, Arlington, TN, USA). Calcium 
sulphate in its set form has a compressive strength greater than cancellous bone and a tensile 
strength slightly less than cancellous bone. Calcium sulphate, however, requires a dry 
environment to set and if it is re-exposed to moisture it tends to soften and fragment. For this 
reason it has no reliable mechanical properties in vivo and its application should be limited to a 
contained area. Hence the primary use of calcium sulphates should be as bone void filler.                                                                                                                
Bioactive glass is a silicone-based, osteoconductive material that bonds to bone through the 
formation of carbonated hydroxyapatite. When exposed to tissue fluids, bioactive glasses are 
covered by a double layer composed of silica gel and a calcium-phosphorous rich (apatite) layer. 
The later promotes adsorption and concentration of proteins utilized by osteoblasts to form a 
mineralized extracellular matrix. It has been believed that these bioactive properties guide and 
promote osteogenesis, allowing rapid formation of bone. Examples of bioactive glasses 
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commercially available are Perioglas® (Block Drug Co., NJ, USA) and Biogran® (Orthovita, PA, 
USA).                                                                                                         
HTRTM synthetic bone (Bioplant, CT, USA) is a biocompatible microporous composite of 
methylmethacrylate and hydroxymethylmethacrylate polymers and calcium hydroxide. HTR 
stands for hard tissue replacement. Its hydrophilicity enhances clotting, and its negative particle 
surface charge allows adherence to bone. It appears to serve as a scaffold for bone formation 
when in close contact with alveolar bone. Histological evidence of new bone formation on 
HTRTM particles has been reported.                                                            
Alloplasts can be mixed with autogenous grafts or allografts in the management of large 
structural defects. Some alloplastic materials are mixed together to achieve superior results. 
Fortoss® Vital (Biocomposites, Staffordshire, UK) is such a mixture of beta tricalcium phosphate 
and calcium sulphate. This can be used for guided tissue regeneration without an additional 
membrane as calcium sulphate serves the purpose of a membrane.  
To conclude, bone grafting is now a well-recognized choice in the treatment of periodontal 
osseous defects, especially when used along with barrier membranes. Various types of bone 
grafts and also their combinations are used with varying degrees of success. Rapid developments 
in this particular field are leading us towards achieving the ultimate goal in periodontal therapy, 
which is the regeneration of lost periodontal tissues. Although complete regeneration is now a 
distant dream, the use of bone grafts enabled us to inch towards it. Autografts are still considered 
the ideal grafts but for the difficulty in obtaining it. So with the source limitations of autogenous 
bone and concerns regarding allogenic bone, the role of bone substitutes will likely to increase. 
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Future of bone grafts is likely to lie in the industrially manufactured biomaterials in combination 
with laboratory-grown cells developed by tissue-engineering. 
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2 AIM OF THE STUDY 
The study was aimed towards the long-term clinical evaluation of the effectiveness of a 
composite material, beta tricalcium phosphate in combination with calcium sulphate, in the 
treatment of periodontal osseous defects. Intra-bony defects remain a significant therapeutic 
problem in periodontal therapy. Regeneration of lost periodontal tissues is the ideal goal in the 
treatment of periodontal defects. Bone grafts are used mainly for the filling of the bony defects 
thereby aiding in regeneration. The indications of various bone grafts in periodontal therapy are 
similar, but the search for the ideal material is still on. This study was focused on one such 
synthetic graft material which could be superior to other graft materials in terms of clinical 
outcome and usage owing to its properties.  
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3 OUTLINE OF THE STUDY 
 
This long-term retrospective follow-up study was designed to evaluate the clinical outcome of 
guided tissue regeneration with a synthetic bone graft material.  
Forty-seven intrabony defects in twenty-six periodontitis patients were treated with the bone 
replacement composite graft material beta tricalcium phosphate in combination with calcium 
sulphate. Patients were recalled for the postoperative care at two weeks, three months, six 
months, one year and two years.  
Clinical parameters were evaluated which included changes in probing depth (PD), clinical 
attachment level/loss (CAL) and gingival recession (GR) at the baseline (preoperative), at one-
year and two-years postoperatively along with the various factors like presence of plaque, 
bleeding on probing (BOP) and smoking.  
The preoperative measurements were compared to the postoperative measurements at one and 
two years to determine whether the technique had a statistically significant effect on the outcome 
of the treatment. Other factors like sex, smoking, oral hygiene were also evaluated to determine 
whether they could be related to improved or diminished results. Radiographs were made 
preoperatively and at one and two years postoperatively. 
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4 MATERIALS AND METHODS 
 
4.1 Subjects 
In this study twenty six patients who were consecutively treated using the composite bone 
replacement graft material were evaluated. These patients had moderate to advanced chronic 
periodontitis, were in general good health presented with at least one deep intrabony defect and 
were treated in the Division of Periodontology, Department of Dentistry, Faculty of Medicine in 
Hradec Králové, Czech Republic. They were aged 21 to 58 years with a mean age of 
42.27±10.66 at the time of surgery. There were 9 males and 17 females (Fig. 4.1), out of which 8 
were smokers (Fig. 4.2). All the smokers were medium smokers, smoking up to 5 cigarettes a 
day. 
Figure 4.1 
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Figure 4.2 
 
Subject inclusion was based on the presence of at least one tooth with a probing depth (PD) of ≥ 
5 mm and radiographic evidence of intrabony defect after initial phase of periodontal therapy. 
The exclusion criteria consisted of patients with systemic diseases or medically compromised 
conditions and taking any drug known to interfere with the wound healing during the previous 
six months, pregnant and/or lactating women and insufficient dental hygiene characterized by a 
papilla bleeding index (PBI) total score of >15. Teeth had to be vital or properly treated with root 
canal therapy. Signed consent forms before surgeries were obtained from the patients.  
Each patient received an initial periodontal treatment including oral hygiene instructions, plaque 
control and full mouth scaling and root planning. Persistent deep periodontal pockets (PD ≥ 5 
mm) with bleeding on probing (BOP) after the initial phase therapy and the maintenance phase 
varying between two to four months were considered for the surgical treatment with the bone 
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graft material. Radiographic assessment of the sites provided further evidence of intrabony 
defects. A total of forty seven teeth (33 frontals + 7 premolars + 7 molars) with intrabony defects 
which were two or three-walled in twenty six patients were treated in a period of about two years 
at our clinic (Fig. 4.3).  
Figure 4.3 
 
 
 
4.2 Materials 
4.2.1 Fortoss® Vital 
Fortoss® Vital (Biocomposites, Staffordshire, UK) which is a comparatively newer biphasic 
calcium composite material composed of a porous beta tricalcium phosphate and calcium 
sulphate is being used in the treatment of periodontal intrabony defects in our dental clinic since 
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the year 2003. Due to a modified surface activity and ion loading, its osteoconductive behaviour 
seems to be superior if compared to conventional calcium phosphates. This material has the 
benefit of being both a graft material and an integral membrane produced within one mixture. 
The beta tricalcium phosphate acts as a slowly resorbing matrix that is substituted by bone. The 
calcium sulphate sets hard and acts as a resorbable membrane that stabilises the graft but 
excludes any competitive cells. It also exhibits Zeta Potential Control (ZPC™, Biocomposites, 
Staffordshire, UK) which is claimed to enhance bone growth by attracting bone proteins into the 
site from the surrounding tissues. Fortoss® Vital is supplied as a sterile, sealed and disposable kit. 
The kit consists of a vial containing the graft powder, a solution container, a pipette, a mixing 
bowl and a spatula (Fig. 4.4). 
Figure 4.4 
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4.2.2 Tetracycline hydrochloride 
Tetracycline hydrochloride solution was prepared by slowly adding tetracycline hydrochloride 
powder into distilled water until a saturated solution of approximately 50 mg/ml concentration 
was obtained with constant stirring (Fig. 4.5). Topical tetracycline HCL conditioning removes 
the smear layer and is believed to enhance fibroblast attachment and growth, while suppressing 
epithelial cell attachment and growth and also has an anticollagenase action. Furthermore, topical 
tetracycline HCl is adsorbed to and released from the dentin surface maintaining an antimicrobial 
property for at least fourteen days post therapy. 
Figure 4.5 
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4.3 Methods 
4.3.1 Pre-surgical phase 
The pre-surgical phase consisted of proper evaluation and selection of periodontal intrabony 
defects for surgery following initial phase periodontal therapy. Initial phase of treatment 
consisted of controlling the etiological factors, thereby halting the further progression of the 
disease. This phase, also called as etiologic or hygienic phase, included patient motivation and 
education in matters of oral hygiene, elimination of supragingival and subgingival dental 
calculus and contaminated radicular cementum and modification/elimination of other plaque 
retentive features like restoration overhangs. Teeth with hopeless prognoses were duly extracted. 
The standard procedure employed for elimination of subgingival calculus and other unwanted 
contents of the periodontal pocket was scaling and root planing (SRP) using a set of Gracey’s 
curettes (Hu-Friedy, Chicago, IL, USA) (Fig. 4.6). Once the subgingival treatment was 
completed, patients were recalled after 6-8 weeks for follow-up. In the follow-up examination, 
oral hygiene was assessed and periodontal probing depths were measured again. To ensure the 
uniformity in the probe diameter, a Williams probe (Hu-Friedy, Chicago, IL, USA) was used 
throughout the study (Fig. 4.7). The surgical treatment phase was initiated after completion of 
the initial phase of periodontal therapy and scheduled recall. The sites for surgical treatment 
were selected, during the recall phase, according to the presence of deep periodontal pockets 
with bleeding on probing (BOP) with radiographic evidence of intrabony defects. 
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Figure 4.6 
 
 
Figure 4.7 
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4.3.2 Surgical phase 
Surgical phase was initiated only if the patients were presented with adequate oral hygiene. 
Signed informed consents were obtained from all patients before surgery.  
All the patients were treated under local anaesthesia (Articaine hydrochloride 4% with 1: 
120,000 epinephrine hydrochloride). After achieving sufficient local anaesthesia, full-thickness 
mucoperiosteal flaps were elevated using a crevicular incision on the facial and lingual surfaces 
of each tooth, segment or area involved. In the upper anterior regions papilla preservation 
incisions were made in the interdental area (Fig. 4.8). Vertical release incisions were used as 
necessary. Surgical scalpels number 11, 15 and a micro scalpel number 67 (Fig. 4.9). After the 
elevation of the flap (Fig. 4.10) using periodontal periosteal elevators (Fig. 4.11), a thorough root 
surface debridement was done using Gracey or universal curettes. All granulomatous tissue were 
removed from the osseous defects and rinsed with saline (Fig. 4.12). Root surface conditioning 
was done using 2.5% tetracycline hydrochloride for 2-3 minutes followed by flushing with 
saline. Fortoss® Vital powder is mixed with the fluid supplied along with it in to a gritty 
mouldable paste and applied it in layers using a sterile instrument (Fig. 4.13, 4.14). The graft 
material was firmly pressed into the site using finger pressure over sterile gauze. The defects 
were over-packed to allow for any settling of the mixture (Fig. 4.15). Any excessive blood was 
removed from the site by using damp sterile gauze. Then the gauze was held on the graft for a 
few seconds. The mucoperiosteal flaps were approximated and sutured (Fig. 4. 16). The sutures 
used were resorbable sutures (Safil®, Braun, Tuttlingen, Germany) (Fig. 4.17). 
 
 
 
 71 
 
 
Figure 4.8 
 
 
 
 
 
 
 
  
 
 
 
 
Crevicular and papilla preservation incision (arrows) along with vertical incisions made to 
expose the intrabony defect related to the upper left central incisor in a patient. 
 
Figure 4.9 
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Figure 4.10 
 
 
 
 
 
 
 
 
 
 
 
 
Full-thickness mucoperiosteal flap elevated 
 
 
 
Figure 4.11 
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Figure 4 .12 
 
 
 
 
 
 
 
 
 
 
 
 
Defect mechanically debrided and rinsed with saline. 
 
Figure 4. 13 
 
 
 
 
 
 
  
 
 
 
 
 
 
Fortoss ® Vital powder and fluid with dropper as supplied by the manufacturer.  
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Figure 4.14 
 
 
Powder mixed with fluid in to a gritty mouldable paste 
 
Figure 4.15 
 
 
 
 
 
 
 
 
 
 
 
 
Graft material applied in to the bony defect 
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Figure 4.16 
 
 
 
 
 
 
 
 
 
 
Sutures placed 
 
Figure 4. 17 
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4.3.3 Post-surgery 
The patients were given post-operative instructions including rinsing with Listerine® (Johnson & 
Johnson, Maidenhead, UK) mouth rinse for two weeks. Antibiotics (Amoxicillin 250 mg with 
clavulanic acid 125 mg or clarithromycin 250 mg) were prescribed post-operatively as surgical 
prophylaxis to the patients for 7 - 14 days. The sutures were removed after two weeks and the 
surgical sites were cleansed gently with 3% hydrogen peroxide using a cotton swab. The patients 
were scheduled for recall visits at 3, 6, 12 and 24 months postoperatively. Oral hygiene was 
evaluated and supragingival prophylaxis was carried out at each recall visit. Clinical parameters 
were also measured during the recall visits. 
4.3.4 Clinical measurements 
The clinical measurements were performed by two examiners randomly. Both the examiners 
recorded similar measurements during a two year trial period of cross-checking. Clinical 
parameters were recorded just before the surgery (baseline) and at one and two years 
postoperatively. These included probing depth (PD), gingival recession (GR), clinical attachment 
level/loss (CAL), presence/absence of dental plaque on the mesial and distal tooth surfaces, and 
bleeding on probing (BOP). The measurements were done using a calibrated periodontal probe 
(Williams colour coded, Hu-Friedy, Chicago, IL, USA) at the buccal/vestibular, lingual/oral, 
mesial and distal surfaces on all teeth involved and the highest value for each surface was 
quoted.    
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4.3.5 Radiographs 
 
Intraoral periapical radiographs were taken at the baseline and at 2 years postoperatively. The 
radiographs were used only for the detection of bone fill in the defects and not for the 
measurements as the method employed were not standardized. Post-operative radiographs were 
compared to the ones at the baseline in order to evaluate the bone fill and also to compare that 
with the clinical measurements.  
 
4.3.6 Statistical methods 
 
Comparisons between baseline and one year and that between baseline and two year data were 
made using paired t-tests and Fisher’s exact tests. Mean differences in the PD, GR and CAL 
were calculated on individual surfaces separately as well as together. The changes in other 
variables like BOP and plaque deposits were also evaluated. All the surfaces of an involved tooth 
were taken into account irrespective of the presence/absence of PD ≥ 5mm. This was done to 
assess the outcome of surgery on the non-involved sites of the involved tooth as well. Data were 
expressed as means ± standard deviation. The level of significance was set at 0.05. 
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5 RESULTS 
 
Clinically, the graft material used was easy to handle, strongly adherent, packed well into 
defects, appeared to harden as a solid in a few minutes and biocompatible. Wound healing was 
uneventful. No patients reported a significant postoperative pain during the first week. 8 patients 
did not turn up for all scheduled recall visits. All of them reported at 2 years postoperatively. 
A decrease in probing depths (PD) was noticed in 24 patients out of the total 26 at one year 
postoperatively. At 2 years postoperatively, a decrease in PDs was found in all patients but one. 
The number of BOP positive sites in relation to the involved teeth was reduced from 67 (35.64 
%) at baseline to 26 (13.83 %) at 1 year and 28 (14.89 %) at 2 years postoperatively. The number 
of sites with presence of plaque got decreased from 25 (26.60 %) to 15 (15.96 %) and then 
increased slightly to 18 (19.15 %) during the same interval. The difference between the 
percentage of plaque deposits at the baseline and 1 year and between baseline and 2 years were 
statistically significant as shown in Table 5.1. 
 
Table  5.1 
Plaque and bleeding on probing (BOP) sites at the baseline and at 1 and 2 years postoperatively 
  Parameter   Baseline   1 year   2 years        P 
  Plaque   35. 64 %   13.83 %   14.89 %     0.0001 
  BOP 26.60 % 15.96 % 19.15 % 0.0001 
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The mean PD was 4.07 ± 2.63 mm at the baseline and 2.10 ± 1.29 mm at 1 year postoperatively 
and 2.0 ± 1.2 mm at 2 years postoperatively. When only the deepest probing measurements (≥ 5 
mm) corresponding to deep intrabony defects were considered, the mean PD was 6.67 ± 1.49 
mm at the baseline and 2.67 ± 1.35 mm at 1 year and 2.60 ± 1.46 mm at 2 years postoperatively 
(Tab. 5.2). 
Table 5.2 
Probing depth (PD) measurements (mean values) at baseline, 1 year and 2 years postoperatively 
Mean PD (mm) Baseline 1 year 2 year 
Total measurements 
around involved tooth 
4.07 ± 2.63 2.10 ± 1.29 2.0 ± 1.2 
Single deepest 
measurement 
representing intrabony 
defect 
6.67 ± 1.49 2.67 ± 1.35 2.60 ± 1.46 
 
Similarly, the mean CAL was 5.66 ± 3.10 mm at the baseline and 3.94 ± 1.96 mm at 1 year 
postoperatively and 3.73 ± 1.90 mm at 2 years postoperatively. When only the deep probing 
measurements corresponding to deep intrabony defects were considered, the mean CAL was 7.66 
± 2.29 mm at the baseline and 4.72 ± 1.87 mm at 1 year and 4.43 ± 1.95 mm at 2 years 
postoperatively (Tab. 5.3). 
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Table 5.3 
Clinical attachment level (CAL) measurements (mean values) at baseline, 1 year and 2 years 
postoperatively 
Mean CAL (mm) Baseline 1 year 2 year 
Total measurements 5.66 ± 3.10 3.94 ± 1.96 3.73 ± 1.90 
Single deepest 
measurement 
7.66 ± 2.29 4.72 ± 1.87 4.43 ± 1.95 
 
The changes in parameters illustrated in the tables 5.2 and 5.3 between baseline and 1 year 
postoperatively and between baseline and 2 years postoperatively were statistically significant 
with p values less than 0.0001. The differences in parameters between 1 and 2 years 
postoperatively were not found to be statistically significant with p values greater than 0.05. 
 
Tables 5.4, 5.5 and 5.6.A and B show the differences in deep probing depth measurements at the 
baseline, at 1 year and at 2 years postoperatively. There were a total of 83 PD measurements in 
those 47 involved teeth which were ≥ 5 mm at the baseline. A 1 year postoperative recall check 
showed a significant decrease in this number to 14. At 2 years postoperatively, this number was 
found to be 13. There was a significant decrease in the numbers in relation to the frontal teeth, 
but a perfect outcome was resulted in case of these numbers in molars and also in the vestibular 
aspect of all teeth involved.  
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Table 5.4 
PD measurements ≥ 5 mm at baseline 
Teeth V M O D 
Frontal 8 27 11 11 
Premolar 0 4 3 4 
Molar 1 6 3 5 
Total 9 37 17 20 
V = vestibular/buccal, M = mesial, O = oral/lingual, D = distal 
 
Table 5.5 
PD measurements ≥ 5 mm at 1 year postoperatively 
Teeth V  M  O  D  
Frontal 0 4 4 4 
Premolar 0 2 0 0 
Molar 0 0 0 0 
Total  0  6 4 4 
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Table 5.6.A 
PD measurements ≥ 5 mm at 2 years postoperatively 
Teeth V M O D 
Frontal 0 4 3 4 
Premolar 0 2 0 0 
Molar 0 0 0 0 
Total 0 6 3 4 
 
Table 5.6.B 
Graphic representation of distribution of probing depths ≥ 5 mm 
 
 
 84 
 
 
Tables 5.7, 5.8 and 5.9 show how the CAL measurements fared during the same period. Total 
CAL measurements of ≥ 5 m at the baseline was 105 which got reduced by almost half to 61 at 1 
year and 54 at 2 years postoperatively. Again, the numbers were much more significant in 
relation to the frontal teeth and in the proximal and oral aspects.  
 
Table 5.7 
CAL measurements ≥ 5 mm at baseline 
Teeth V M O D 
Frontal 9 27 20 16 
Premolar 0 4 3 6 
Molar 4 7 4 5 
Total 13 38 27 27 
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Table 5.8 
CAL measurements ≥ 5 mm at 1 year postoperatively 
Teeth V  M  O  D  
Frontal 4 12 7 10 
Premolar 0 4 1 4 
Molar 4 6 4 5 
Total 8  22  12  19  
 
Table 5.9 
CAL measurements ≥ 5 mm at 2 years postoperatively 
Teeth V M O D 
Frontal 7 17 8 10 
Premolar 0 0 1 1 
Molar 3 4 1 2 
Total 10 21 10 13 
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The mean differences in measurements between the baseline and one year postoperatively are a 
reduction of 1.97 ± 1.15 mm (P= 0.0001) in case of PD, a gain of 1.68 ± 1.12 mm (P = 0.0001) 
in CAL and an increase of 0.30 ± 0.71 mm (P = 0.009) in GR. The mean differences in 
measurements between the baseline and two years postoperatively are a reduction of 2.07 ± 1.14 
mm (P = 0.0001) in case of PD, a gain of 1.93 ± 1.36 mm (P = 0.0001) in CAL and an increase 
of 0.14 ± 0.73 mm (P = 0.571) in GR. These are illustrated in tables 5.10-5.16. No significance 
was found statistically between the results after 1 and 2 years postoperatively (P > 0.05 in case of 
difference in means: CAL, PD and GR) 
 
Table 5.10 
Mean difference in gingival recession (GR) measurements at baseline and 1 year postoperatively 
GR 
( Increase= “+”, decrease=“ –“ ) 
V M O D Average 
+ 0.50 (-1 to 3) 
SD: ± 0.99 
+ 0.18 (-3 to 3) 
SD: ± 1.18 
+ 0.38 (-2 to 2) 
SD: ± 0.97 
+ 0.26 (-3 to 3) 
SD: ± 1.51 
+ 0.30  
SD: ± 0.71 
(Values in millimetres, maximum and minimum values in brackets, SD- standard deviation) 
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Table 5.11 
Mean difference in gingival recession (GR) measurements at baseline and 2 year postoperatively 
GR 
( Increase= “+”, decrease=“ –“ ) 
V M O D Average 
+ 0.40  (-2 to 3) 
 
 
SD: ± 1.17 
- 0.06 (-2 to 3) 
 
 
SD: ± 1.11 
 
+ 0.27 (-2 to 3) 
 
 
SD: ± 0.94 
 
- 0.04 (-3 to 2) 
 
 
SD: ± 1.33 
 
+ 0.14 
 
 
SD: ± 0.73 
 
  
 
Table 5.12 
Mean difference in clinical periodontal probing depth (PD) measurements at baseline and 1 year 
postoperatively 
PD 
( Increase= “+”, decrease=“ –“ ) 
V M O D Average 
- 0.89 (-7 to 3) 
SD: ±1.91 
- 3.10 (-9 to 5) 
SD: ±2.75 
- 1.51 (-6 to 2) 
SD: ±1.99 
- 2.38 (-9 to 1) 
SD: ±2.26 
- 1.97 
SD: ±1.15  
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Table 5.13 
Mean difference in periodontal probing depth (PD) measurements at baseline and 2 year 
postoperatively 
PD 
( Increase= “+”, decrease=“ –“ ) 
V M O D Average 
- 0.96 (-6 to 1) 
 
 
SD: ± 1.18 
 
- 3.49 (-8 to 2) 
 
 
SD: ± 2.47 
 
- 1.74 (-6 to 2) 
 
 
SD: ± 2.16 
 
- 2.11 (-9 to 1) 
 
 
SD: ± 2.15 
 
- 2.07 
 
 
SD: ± 1.14 
 
 
Table 5.14 
Mean difference in clinical attachment level (CAL) measurements at baseline and 1 year 
postoperatively 
CAL 
( Gain= “+”, Loss= “-”) 
V M O D Average 
+ 0.36 (-2 to 7) 
SD: ± 1.88 
+ 2.94 (-4 to 9) 
SD: ± 2.89 
+ 1.13 (-2 to 5) 
SD: ± 2.10 
+ 2.10 (-3 to 8) 
SD: ± 2.59 
+ 1.68  
SD: ± 1.12 
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Table 5.15 
Mean difference in clinical attachment level (CAL) measurements at baseline and 2 years 
postoperatively 
CAL 
( Gain= “+”, Loss= “-”) 
V M O D Average 
+ 0.55 (-3 to 6) 
SD: ± 1.95 
+ 3.55 (-2 to 9) 
SD: ± 2.60 
+ 1.48 (-3 to 6) 
SD: ± 2.36 
+ 2.13 (-3 to 8) 
SD: ± 2.54 
- 1.93 
SD: ± 1.36 
 
Table 5.16 
Mean differences and corresponding p values 
 
Parameter 
(change) 
Mean difference 
between baseline 
and 1 year 
 
p 
Mean difference 
between baseline 
and 2 years 
 
p 
CAL (gain) 1.68 ± 1.12 mm 0.0001 1.93 ± 1.36 mm 0.0001 
PD (reduction) 1.97 ± 1.15 mm  0.0001 2.07 ± 1.14 mm  0.0001 
GR (increase) 0.30 ± 0.71 mm 0.009 0.14 ± 0.73 mm  0.571 
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There were no significant differences between smokers and non-smokers (p = 1.000). But in one 
patient where an increase in PD and CAL were noticed 2 years after the surgery, a combination 
of different factors like smoking, bad oral hygiene and non-compliance with the follow-up 
schedule during the maintenance phase after surgery were present.  
Intraoral periapical radiographs showed bone fill in the defects in patients where PD got reduced 
after the surgical treatment (Tab. 5.17). 
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Table 5.17.: Comparison of intraoral periapical radiographs at the baseline and at 2 years 
postoperatively 
 Baseline 2 years postoperatively 
1) 
 
 
2) 
 
 
3) 
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6 DISCUSSIONS 
Bone grafting is now a well-recognized choice in the treatment of periodontal osseous defects, 
especially when used along with barrier membranes. Various types of bone grafts and also their 
combinations are used with varying degrees of success. Autografts have been considered to be 
the gold standard among bone replacement grafts as they can induce osteogenesis.56, 70, 111 
However, there are some limitations for the autografts like a surgical donor site is needed and 
availability of graft bone is limited. The alloplastic grafts or synthetic bone graft substitutes as 
yet offer only a part solution to the management of localized bone loss. They possess some of the 
desired mechanical qualities of bone as well as osteoconductive properties but are largely reliant 
on viable periosteum/bone for their success. They primarily serve as defect filler. In the present 
study, we have evaluated the effectiveness of a novel composite alloplast in the treatment of 
periodontal intrabony defects. 
6.1 Discussion on the graft material Fortoss® Vital 
Fortoss® Vital which is a combination of beta tricalcium phosphate and calcium sulphate is being 
used in the treatment of periodontal intrabony defects in our department since the year 2003. The 
main reasons for the choice of this bone graft material over the conventional membrane and graft 
technique to achieve periodontal regeneration are non-requirement of a membrane, reduced 
surgical time, lesser cost and the ease and potential to treat periodontal intrabony defects 
spanning more than 2 teeth. After all, the surface characteristics of the material might promote an 
optimal integration of the graft material with a favourable healing outcome. According to the 
manufacturers the material possesses an electronegative surface charge (negative Zeta potential) 
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and this will make it more accessible for the attachment and proliferation of osteoblasts than 
surfaces with no or even positive electric charge. 
The use of a composite graft containing beta tricalcium phosphate and calcium sulphate was 
described in only a few reports and studies.126, 157, 163, 164 In those reports and studies it was found 
that the use of this particular graft provided good results. In a clinical study published in 2009 by 
Stein et al, it was found that the clinical benefits of a biphasic composite graft containing beta 
tricalcium phosphate and calcium sulphate were equivalent to that of autogenous bone spongiosa 
and superior to that of OFD alone. At 12 months postoperatively, the patients treated with the 
composite graft exhibited a mean PD reduction of 3.6 ± 0.7 mm and a mean CAL gain of 3.0 ± 
0.8 mm.157 The study done on the iliac crest of dogs by Podaropoulos et al. in 2009 revealed that 
the mean percentage of new bone regeneration after 4 months by histological evaluation and 
morphometric analysis was 49.38 %.126 Structurally porous beta tricalcium phosphate has a 
compressive strength and tensile strength similar to that of cancellous bone. It undergoes 
resorption over a 6-18 month period. Calcium sulphate has a compressive strength greater than 
that of cancellous bone. It can act as a barrier membrane as well, which makes it ideal for using 
as an adjunct with other graft materials. It requires only 5-7 weeks for complete resorption .20, 158  
6.2 Discussion on methods 
Measurement methods for the assessment of clinical outcome variables, such as probing depths, 
attachment level and gingival recession, have varied between studies, particularly with regard to 
the use of automatic or pressure sensitive or conventional probes and the use of a stent as a 
reference point. 132 The key element is the consistency of the assessment throughout the study. In 
the present study, an occlusal stent was not fabricated; the cement enamel junction and the free 
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gingival margin served as the reference point. Manual probes were used to measure the variables. 
The ability of a probe to penetrate into a periodontal pocket is related to several factors like the 
probing force, diameter of the probe and the gingival tissue tone. 5, 79, 137 In our study, Williams 
colour-coded probe (Hu-Friedy, Chicago, IL, USA) was used throughout in order to ensure the 
consistency in probe diameter. The clinical measurements were performed by 2 examiners 
randomly. Both the examiners recorded similar measurements during a 2 year trial period of 
cross-checking which ensured the similarity in probing force and method. Gingival tissue 
consistency may be modified after the placement of graft material in to the defect, which in turn 
can impede penetration of the periodontal probe causing false positive results.28  
Unlike usual studies, we have considered the unaffected sides of the tooth as well. We have done 
this as the surgical wound included all the sides of the tooth and surgery as such can have an 
effect on the unaffected sides as well. The intrabony defects in this study varied in terms of the 
depth and type of the defect. There were 2 and 3 walled defects. The sample size used in this 
study was relatively small, but it was within the range of most periodontal regenerative studies.60 
Although standardised radiographs were not made in this study, 2 years after treatment 
radiographic defect fill with bone-like radio opaque tissue, which was indistinguishable from 
native bone and therefore considered as new bone, was observed. The shortcomings of the study 
could be a small patient group, no standardised radiographic analysis or surgical re-entry to 
establish the bone fill or regeneration, the non-usage of stents during clinical measurements and 
also the non-involvement of a control group in which another surgical technique or material was 
used.  
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Conventional therapy is capable of controlling periodontal disease. Scaling and root planning 
allow reduction in pocket depth mainly by new connective tissue or epithelial attachment; with a 
probable gain in clinical attachment level. Periodontal literature is sated with studies showing the 
treatment of periodontitis by scaling and root planing results in reductions of probing depth.9, 35, 
67, 68
 The decrease in probing depth is caused partly by the shrinkage of the pocket soft tissue 
wall manifested as recession of the gingival margin which results from a decrease in soft tissue 
inflammation; and partly from the gain in clinical attachment.9, 35, 67, 68 In a thorough evidence-
based review, Cobb calculated the mean probing depth reduction and gain of clinical attachment 
that can be achieved with root planing at sites that initially were 4 to 6 mm in depth and 7 mm or 
greater in depth. He reported mean pocket depth reductions of 1.29 mm and 2.16 mm, 
respectively, and mean gains of clinical attachment of 0.55 mm and 1.29 mm, respectively.35  
The regenerative procedures are performed after the conventional scaling and root planing to 
attain further improvement of the tissues destroyed by periodontitis. These procedures can 
promote further bone fill, thus improving the supporting structures thereby improving the long-
term prognosis of the tooth.  
6.3 Discussion on results 
Results from present investigation showed that the graft material used was effective in 
significantly improving the clinical parameters at 1 and 2 years after surgery. The overall 
reduction in PD and gain of attachment were found to be highly statistically significant and the 
mean difference in GR between the baseline and at 2 years postoperatively was negligible and 
not significant statistically. Ideally, a comparative study with open flap debridement and/or using 
a different bone graft material in treating comparable defect pairs would have been more 
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significant to highlight the outcome of treatment using Fortoss® Vital.  The amount of PD 
reduction was found to be greater in the deeper defects. In some cases, this reduction was up to 9 
mm. PD reduction was achieved in 25 of the total 26 patients; there was an increase of PD in one 
patient 2 years postoperatively. The local factors and the non-compliance of the patient probably 
would have resulted in the undesired result. After 2 years, the number of sites with bleeding on 
probing was reduced to almost half. The number of proximal sites (mesial and distal) with plaque 
deposits also got reduced. 
Several studies were done to evaluate the effectiveness of calcium sulphate and of beta 
tricalcium phosphate in combination with other materials resulting in good clinical outcomes. A 
study by Harris in 2004 evaluating a composite bone graft (demineralised freeze-dried bone 
allograft, calcium sulphate, tetracycline and porous hydroxyapatite) and calcium sulphate barrier 
showed a mean decrease of 4.7 mm of PD, 3.7 mm of CAL and a mean increase of 1.0 mm of 
GR at 4-6 months postoperatively.72 In another study by Paolantonio et al. using  calcium 
sulphate barrier implant and barrier revealed a mean decrease of 4.4 mm of PD, 2.7 mm of CAL 
and a mean increase of 1.6 mm of GR at 12 months postoperatively.119 In a study published in 
2008 by Döri, at 1 year after therapy, the sites treated with platelet rich plasma+ β-TCP + GTR 
showed a reduction in mean PD from 9.1 ±0.6 mm to 3.3 ±0.5 mm (P<0.001) and a change in 
mean CAL from 10.1 ± 1.3 mm to 5.7 ±1.1 mm.45 Most of these studies used clinical 
measurements along with standardized radiographs for comparison. Unlike the present study, all 
these studies were short-term studies and have considered only the affected area around the 
tooth, where the pocket depths were deeper, which may influence the results. 
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We have used tetracycline HCl solution for root conditioning during the surgery. Topical 
tetracycline HCl conditioning removes the smear layer and is believed to enhance fibroblast 
attachment and growth, while suppressing epithelial cell attachment and growth 8 and also has an 
anti-collagenase action.159 Furthermore, topical tetracycline HCl is adsorbed to and released from 
the dentin surface maintaining an antimicrobial property for at least fourteen days post therapy. 
156
 However, root conditioning using tetracycline HCl application has not proven to be beneficial 
in terms of clinical significance to periodontal regeneration.95 
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7 CONCLUSIONS 
Within the limitations of this retrospective study, the following conclusions were drawn: 
• The treatment with a synthetic bone graft containing a combination of beta tricalcium 
phosphate and calcium sulphate led to a significantly favourable clinical improvement in 
periodontal intrabony defects two years after the surgery.  
• The graft material was easy to handle, strongly adherent, packed well into defects, 
appeared to harden as a solid in a few minutes and biocompatible. 
• There was a statistically significant difference in terms of clinical attachment level (CAL) 
and periodontal probing depth (PD) between the baseline and one year postoperatively 
and between baseline and two years postoperatively. Even though there was a slight 
positive difference between one and two year results clinically, the difference was not 
statistically significant. 
• A much longer term evaluation and further studies are necessary to completely ascertain 
the effectiveness of this material, and a larger sample size is also recommended. Also, 
standardized radiographic or a surgical re-entry is recommended for confirmation of the 
clinical results. 
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8 CLINICAL IMPLICATIONS 
• From this study, it became evident that treatment of periodontal intrabony defects with 
the new graft material Fortoss® Vital offers a method to achieve significant probing 
depth reduction and shallow residual pockets, which are considered important for 
maintaining periodontal health and improving the prognosis of treated teeth.  
• Fortoss® Vital can be prescribed in the treatment of 2 or 3-walled periodontal intrabony 
defects. 
• The ease with which this material can be manipulated and its property of being a graft 
material and an integral membrane in one mixture allows an easy and predictable way of 
guided tissue regeneration procedure. 
• The main reasons for the choice of this bone graft material over the conventional 
membrane and graft technique to achieve periodontal regeneration are non-requirement 
of a membrane, reduced surgical time, lesser cost and the ease and potential to treat 
periodontal intrabony defects spanning more than 2 teeth. 
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